Getinge AB (GTN.BE)
| Previous close | 19.98 |
| Open | 19.59 |
| Bid | 19.80 x 0 |
| Ask | 20.19 x 0 |
| Day's range | 19.59 - 19.59 |
| 52-week range | 14.86 - 22.67 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 2-US FDA advises healthcare facilities to switch from Getinge's heart devices
The U.S Food and Drug Administration (FDA) on Wednesday advised healthcare facilities to move away from using Getinge's heart devices in patients as they faced safety and quality concerns despite a string of recalls. Getinge did not immediately respond to a Reuters request for comment. The FDA suggests providers to move away from the use of Getinge's Cardiosave Hybrid and Rescue Intra-Aortic Balloon Pump (IABP) devices and its Cardiohelp system and HLS Sets.
- GuruFocus.com
Getinge AB's Dividend Analysis
Getinge AB (GNGBY) recently announced a dividend of $0.42 per share, payable on 2024-05-14, with the ex-dividend date set for 2024-04-23. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Getinge AB's dividend performance and assess its sustainability.
- Reuters
Medical gear maker Getinge beats profit expectations, shares jump
(Reuters) -Medical equipment maker Getinge reported a smaller than expected drop in first-quarter core profit on Monday, as new orders offset the costs of resolving prolonged problems with its product packaging and heart products. Its quarterly earnings before interest, tax and amortisation (EBITA), adjusted for items affecting comparability, fell 13.4% from a year earlier to 842 million Swedish crowns ($77 million), but exceeded a consensus of 770 million cited by J.P.Morgan. Getinge has struggled to resolve quality problems with sterile packaging of products for heart-lung support systems and with its heart pumps that have squeezed its margins and knocked its shares since the second quarter last year.
